Department of Community Medicine, Kaduna State University, Kaduna State, Nigeria.
Barau Dikko Teaching Hospital, Kaduna State, Nigeria.
West Afr J Med. 2022 Feb 28;39(2):140-146.
Ivermectin has been a popular anti-parasitic drug since the late 1970s. The promising result of in-vitro studies on the antiviral activity of the drug has led clinicians in many countries to use this drug to treat COVID-19 patients. This study determined and compared the mean number of days at clinical recovery for mild to moderate cases of COVID -19 treated with Lopinavir/Ritonavir (Alluvia) and Ivermectin at the Kaduna State Infectious Disease Control Centres.
This was a comparative cross-sectional study conducted among 300 mild to moderate COVID- 19 cases enrolled for the study. The outcome variables were the time required for the resolution of symptoms from the onset and at commencement of the treatment regimens. Data were collected from patient folders using a questionnaire. Data were analysed with the IBM SPSS Version 25.0 and STATA/SE 13. Statistical significance was set at p<0.05.
The mean recovery time (MRT) from symptom onset was significantly lower for Covid-19 patients treated with ivermectin (7.15±4.18 days) compared to lopinavir/ritonavir (9.7±5.3 days), 95%CI=7.37-9.62. Multivariate logistic regression showed that there was no significant relationship between the patients age (AOR=0.36, 95%CI=0.09-1.49), sex (AOR=0.34,95%CI=0.54-5.93), educational status (AOR=1.04, 95%CI=0.3-3.57), marital status (AOR=0.55,95%CI=0.14-2.11) place of treatment (AOR=1.66, 95%CI=0.54-5.11) and MRT. There was also no significant relationship between patients' comorbid chronic illness (AOR=0.83, 95%CI=0.27-2.61) and MRT.
The mean recovery time for COVID-19 patients managed with ivermectin was slightly lower than for the lopinavir/ ritonavir regimen.
Clinical trials to further prove the efficacy of Ivermectin as a supportive therapy in clinical management of mild to moderate cases of COVID-19 in this setting should be carried out.
自 20 世纪 70 年代末以来，伊维菌素一直是一种流行的抗寄生虫药物。该药在体外研究中显示出抗病毒活性的有希望结果，导致许多国家的临床医生将该药用于治疗 COVID-19 患者。本研究旨在确定并比较在卡杜纳州传染病控制中心接受洛匹那韦/利托那韦（Alluvia）和伊维菌素治疗的轻度至中度 COVID-19 患者达到临床康复的平均天数。
这是一项在 300 名轻度至中度 COVID-19 患者中进行的比较性横断面研究，这些患者均被纳入研究。结局变量是从发病开始和开始治疗方案时症状缓解所需的时间。使用问卷从患者档案中收集数据。使用 IBM SPSS 版本 25.0 和 STATA/SE 13 进行数据分析。统计显著性设为 p<0.05。
与洛匹那韦/利托那韦相比，接受伊维菌素治疗的 COVID-19 患者的平均恢复时间（MRT）从症状发作开始显著降低（7.15±4.18 天）95%CI=7.37-9.62。多变量逻辑回归显示，患者年龄（AOR=0.36，95%CI=0.09-1.49）、性别（AOR=0.34，95%CI=0.54-5.93）、教育程度（AOR=1.04，95%CI=0.3-3.57）、婚姻状况（AOR=0.55，95%CI=0.14-2.11）、治疗地点（AOR=1.66，95%CI=0.54-5.11）和 MRT 之间无显著关系。患者合并慢性疾病（AOR=0.83，95%CI=0.27-2.61）与 MRT 之间也无显著关系。
接受伊维菌素治疗的 COVID-19 患者的平均恢复时间略低于洛匹那韦/利托那韦方案。
应在该环境中进行临床试验，以进一步证明伊维菌素作为轻度至中度 COVID-19 临床管理支持性治疗的疗效。
